ALKS.NASDAQAlkermes PLC

Form 4: Alkermes Executive Sells Shares

Sentiment:

Insider Transaction (Form 4)


Craig C. Hopkinson, EVP R&D, Chief Medical Officer of Alkermes plc., sold 9,000 shares of common stock on September 1, 2026 for $46.99 per share.

Summary

  • Option exercise/conversion: acquired 5,000 Ordinary Shares at $24.59 ($122,950) on September 1, 2026; holds 74,389 after (Direct).
  • Open-market sale: disposed of 9,000 Ordinary Shares at $46.99 ($422,874) on September 1, 2026; holds 65,389 after (Direct).
  • Option exercise/conversion: disposed of 5,000 Employee Stock Option (Right to Buy) on September 1, 2026; holds 61,276 after (Direct).

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $422,874 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.

Insider Transactions

Craig C. Hopkinson — Officer (EVP R&D, Chief Medical Officer)

Transaction made under a Rule 10b5-1 trading plan.

DateTransactionSecuritySharesPriceValueHeld After
2026-09-01Option exercise/conversionOrdinary Shares5,000$25$123.0K74,389
2026-09-01Open-market saleOrdinary Shares9,000$47$422.9K65,389
2026-09-01Option exercise/conversionEmployee Stock Option (Right to Buy)5,000——61,276

Key Dates

DateDescription
2026-09-01Option exercise/conversion (5,000 shares)
2026-09-01Open-market sale (9,000 shares)
2026-09-01Option exercise/conversion (5,000 shares)

Keywords

insider transaction, Form 4, ALKS, Alkermes plc., bearish, Craig C. Hopkinson

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.